Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirusc (CMV) Infection Using Bayesian Prediction.

Next Previous
X
Search
Trial Profile

Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirusc (CMV) Infection Using Bayesian Prediction.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Pharmacokinetics

    • Most Recent Events

    • 26 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Planned end date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top